Spots Global Cancer Trial Database for A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days
Official Title: A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days
Study ID: NCT00002136
Interventions
Study Description
Brief Summary: To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
Detailed Description: Patients receive intravenous DS-4152 by infusion once every 21 days; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Therapy Research Ctr, San Antonio, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
